HK Stock Market Move | ANTENGENE-B(06996) rose more than 14%. Claudin 18.2 ADC plans to be included in a groundbreaking therapy.

ANTENGENE-B (06996) rose more than 14%, closing at a 14.66% increase, reaching 6.1 Hong Kong dollars, with a turnover of 38.1357 million Hong Kong dollars. On the news front, on August 11th, the CDE website showed that 6 drugs are planned to be included in breakthrough therapy, including ATG-022. It is reported that ATG-022 is a Claudin 18.2 antibody-drug conjugate developed independently by Deqi Medicine. Previously, the company announced the latest clinical data of ATG-022 at the ASCO GI 2025 conference: in patients with high expression of CLDN18.2 (IHC 2+ 20%), the objective response rate (ORR) was 42.9%, and the disease control rate (DCR) was 95.2%; in patients with low expression of CLDN18.2 (IHC 2+ <20%), the ORR was 30.0%, and the DCR was 50.0%. The company will announce the latest research data of ATG-022 at the ESMO conference in October 2025.